玻璃体内注射雷珠单抗和贝伐单抗治疗新生血管性年龄相关性黄斑变性的视网膜血管大小比较研究

Comparative Retinal Vessel Size Study of Intravitreal Ranibizumab and Bevacizumab in Eyes with Neovascular Age-Related Macular Degeneration.

作者信息

Kurt Muhammed Mustafa, Çekiç Osman, Akpolat Çetin, Aslankurt Murat, Elçioğlu Mustafa Nuri

机构信息

Department of Ophthalmology, Okmeydanı Training and Research Hospital, Istanbul, Turkey.

出版信息

Ophthalmologica. 2017;238(3):147-153. doi: 10.1159/000477180. Epub 2017 Jun 10.

DOI:10.1159/000477180

PMID:28601887

Abstract

PURPOSE

The aim of this paper was to assess and compare the effects of intravitreal ranibizumab and bevacizumab on retinal vessel diameter in eyes with neovascular age-related macular degeneration (AMD).

METHODS

Patients with neovascular AMD who underwent intravitreal injection of either ranibizumab or bevacizumab were included. Noninjected fellow eyes served as a control. The main outcome measures were central retinal artery equivalent (CRAE), central retinal vein equivalent (CRVE), and the artery-vein ratio (AVR).

RESULTS

In the ranibizumab group, the mean CRAE value decreased significantly at 1 week and 1 month (p = 0.002). The AVR value decreased significantly at 1 month (p = 0.028). CRVE values did not change at 1 week and 1 month (p = 0.083). In the bevacizumab group, the preinjection CRAE, CRVE, and AVR values did not change through the study period (p = 0.128, p = 0.600, and p = 0.734, respectively).

CONCLUSION

These results suggest that intravitreal ranibizumab led to significant retinal arteriolar vasoconstriction in eyes with neovascular AMD.

摘要

目的

本文旨在评估和比较玻璃体内注射雷珠单抗和贝伐单抗对新生血管性年龄相关性黄斑变性（AMD）患者视网膜血管直径的影响。

方法

纳入接受玻璃体内注射雷珠单抗或贝伐单抗的新生血管性AMD患者。未注射的对侧眼作为对照。主要观察指标为视网膜中央动脉等效直径（CRAE）、视网膜中央静脉等效直径（CRVE）和动静脉比（AVR）。

结果

在雷珠单抗组，1周和1个月时平均CRAE值显著降低（p = 0.002）。1个月时AVR值显著降低（p = 0.028）。1周和1个月时CRVE值未发生变化（p = 0.083）。在贝伐单抗组，整个研究期间注射前的CRAE、CRVE和AVR值均未发生变化（分别为p = 0.128、p = 0.600和p = 0.734）。